Regulatory Sourcebook eBook
Read the article:
Selecting the Right CMC Strategy for Biologics
Read the eBook:
BioPharm International’s Regulatory Sourcebook eBook
Smaller biopharma companies must do due diligence with their CMC strategy for BLA filings.
peshkova/Stock.adobe.com
Advancing a novel biologic from bench to patient bedside is a complex and arduous process. The chemistry, manufacturing, and control (CMC) strategy that a biomanufacturer employs is as critical to the filing of an investigational new drug application or biologics license application as conducting clinical trials. Because there is no one-size-fits-all approach to CMC, the strategy is often tailored to each compound’s specific platform and method of delivery. This is especially true for biologics because each one is unique to the indication and often involves a shortened development timeline.
Read this article in BioPharm International’s October 2021 Regulatory Sourcebook eBook.
Read the article:
Selecting the Right CMC Strategy for Biologics
Read the eBook:
BioPharm International’s Regulatory Sourcebook eBook
Khanh Ngo Courtney, PhD, is senior director of Biologics, Avomeen.
BioPharm International
eBook: Regulatory Sourcebook, October 2021
October 2021
Pages: 18–21
When referring to this article, please cite it as K.N. Courtney, “Selecting the Right CMC Strategy for Biologics," BioPharm International Regulatory Sourcebook eBook (October 2021).
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.